The first drug targeting the cause of Huntington’s disease was safe and well-tolerated in its first human trial led by UCL scientists. It successfully lowered the level of the harmful huntingtin protein in the nervous system.
After over a decade in pre-clinical development, this first human trial of huntingtin-lowering drug began in late 2015, led by Professor Sarah Tabrizi (UCL Institute of Neurology) and sponsored by Ionis Pharmaceuticals.
The trial involved enrolling 46 patients with early Huntington’s disease at nine study centres in the UK, Germany and Canada.
Each patient received four doses of either IONIS-HTTRx or placebo, given by injection into the spinal fluid to enable it to reach the brain. As the phase 1/2a trial progressed, the dose of IONIS-HTTRx was increased several times according to the ascending-dose trial design.
Patient safety was monitored throughout the study by an independent safety committee.
Today’s announcement at completion of the trial confirms that IONIS-HTTRx was well-tolerated by the trial participants and its safety profile supports further testing in patients.
Professor Tabrizi, Director of the UCL Huntington’s Disease Centre and IONIS-HTTRx Global Chief Investigator, said: “The results of this trial are of ground-breaking importance for Huntington’s disease patients and families. For the first time a drug has lowered the level of the toxic disease-causing protein in the nervous system, and the drug was safe and well-tolerated. The key now is to move quickly to a larger trial to test whether the drug slows disease progression.”
A major unknown was whether the trial would show that IONIS-HTTRx could lower the level of mutant huntingtin protein in the nervous system. Using an ultra-sensitive assay, concentrations of the protein were measured in each patient’s spinal fluid before and after treatment.
As hoped, IONIS-HTTRx produced significant, dose-dependent lowering of the level of mutant huntingtin – the first time the protein known to cause Huntington’s has been lowered in the nervous system of patients.
As a result of these successful outcomes, Ionis’ partner, Roche, has exercised its option to license IONIS-HTTRx and assumes responsibility for further development, regulatory activities and commercialization activities. Meanwhile, Ionis announced in June that all patients in the completed trial would be offered a place in an open-label extension to receive IONIS-HTTRx.
Learn more: Drug lowers deadly Huntington’s disease protein
The Latest on: Huntington’s disease
[google_news title=”” keyword=”Huntington’s disease” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Study links agricultural pesticide exposure to increased genetic variants in Parkinson’s diseaseon May 1, 2024 at 3:04 am
Recent research has highlighted the role of autophagic function in PD etiology, with mutations in the glucosylceramidase beta (GBA1) gene increasing the likelihood of developing PD. In the present ...
- Neurocrine Biosciences' Huntington's disease drug gets FDA approvalon April 30, 2024 at 10:22 pm
London: The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' Ingrezza drug to treat movement disorders associated with Huntington's disease (HD), ...
- FDA Approves Neurocrine Biosciences' INGREZZA Sprinkle Capsuleson April 30, 2024 at 6:39 pm
(RTTNews) - The U.S. Food and Drug Administration has approved INGREZZA Sprinkle (valbenazine) capsules, a new oral granules formulation of INGREZZA (valbenazine) capsules prescribed for the treatment ...
- FDA approves Neurocrine Biosciences' Huntington's disease drugon April 30, 2024 at 2:32 pm
The U.S. Food and Drug Administration (FDA) has approved granule formulation of Neurocrine Biosciences' drug to treat movement disorders associated with Huntington's disease, the company said on ...
- Indian-Origin Researcher Unravels Link Between Depression And Heart Diseaseon April 25, 2024 at 12:48 am
Depression and cardiovascular disease (CVD) partly develop from the same gene module, said a team of researchers establish ...
- Link between depression and cardiovascular disease explained: They partly develop from same gene moduleon April 24, 2024 at 9:20 pm
Depression and cardiovascular disease (CVD) are serious concerns for public health. Approximately 280 million people worldwide have depression, while 620 million people have CVD.
- Nanomaterial that mimics proteins could be basis for new neurodegenerative disease treatmentson April 24, 2024 at 5:00 pm
A newly developed nanomaterial that mimics the behavior of proteins could be an effective tool for treating Alzheimer's and other neurodegenerative diseases. The nanomaterial alters the interaction ...
- PTC Therapeutics gets grant for treatment of huntington’s disease using compound of formula (IBBL)on April 22, 2024 at 5:22 am
Discover the latest patent from PTC Therapeutics Inc for treating Huntington's disease with innovative compounds and pharmaceutical compositions. Learn more about the groundbreaking Formula (I) and ...
- Team Hope Walk for Huntington's disease happening this weekendon April 18, 2024 at 8:23 pm
Missouri Chapter will be hosting the Team Hope Walk -- Southeast Missouri on Saturday, April 20, at Jackson City Park in ...
- Reyna’s Tacos to return to help child with rare disease — what you can doon April 17, 2024 at 8:00 am
The family of a 4-year-old San Angelo girl diagnosed with a rare neurological disease is raising funds to pay for a trip to an international conference. Here's how you can help — and walk away with a ...
via Google News and Bing News